Protein Expression Market by System (Mammalian [CHO, HEK 293], Non-mammalian [Bacterial, Insect, Yeast]), Offering (Kits & Reagents, Vectors, Competent Cells, Services), Application (Industrial, Therapeutic, Research), and End User - Global Forecast to 2030

Protein Expression Market is projected to reach $5 billion by 2030, at a CAGR of 7.6% from 2024 to 2030. Protein expression is the process of synthesizing an unnaturally occurring protein (heterologous protein) by introducing recombinant DNA into the host cell. For this, prokaryotic and eukaryotic are used depending on economic and qualitative aspects, such as the type of protein, function, and desired protein yield. These systems are used for therapeutic, research, or industrial purposes.

The increasing biopharmaceutical market, growing demand for recombinant proteins, rising government initiatives, and funding for life science research are driving the growth of this market. Furthermore, the potential emerging economies are expected to offer significant growth opportunities for the protein expression market.

However, the high cost of protein-based research and the lack of skilled professionals are expected to restrain the growth of this market. Additionally, complexities in laboratory transformation parameters are challenging the growth of this market.

Expansion of Biopharma Companies for Production of Biosimilars to Drive the Demand for Protein Expression Market

Biosimilars are gaining significant importance in oncology, autoimmune diseases, and rare diseases. The price advantage of biosimilars compared to biologics and the biosimilar substitution laws are boosting the demand for biosimilars. Several manufacturers are expanding their manufacturing facilities to meet the growing demand for biopharmaceuticals. The COVID-19 pandemic also resulted in the facility expansion of vaccine manufacturing plants. These capacity expansions from biopharmaceutical manufacturers and CDMOs will generate additional demand for biopharmaceutical-related products. For instance,

• In December 2021, Biocon Ltd. (India) and Mylan N.V. (U.S.) planned to combine their biosimilar businesses to create a larger company.

• In December 2021, FUJIFILM Diosynth Biotechnologies (U.S.) announced an investment of USD 350 million to add a current Good Manufacturing Practice (cGMP) production facility at its U.S. plant to increase the production of vaccine manufacturing and advanced therapy.

Biosimilars need to be identical to the biological source; hence the use of protein expression of interest is essential for their production process. Thus, increasing biosimilar production drives the demand for protein expression systems.

Click here to: Get Free Sample Pages of this Report

Emerging Economies Provide Opportunity for the Players in the Market

Developed economies like the U.S. and European countries have contributed greatly to the biopharmaceutical market. These markets are relatively better penetrated, and thus, players in this market are increasingly shifting their focus to underpenetrated emerging economies. Emerging countries in Asia and Latin America offers high growth opportunities attributed to the growing demand for biopharmaceutical products, increasing aging population suffering from chronic and infectious diseases, rising pharmaceutical R&D expenditure, growing demand for biologics, and growing disposable income.

Rising public & private funding for R&D and rising contract research and manufacturing activities support the biopharmaceutical industry's growth across China, India, and the Association of Southeast Asian Nations (ASEAN) member countries in the Asia-Pacific region, Brazil, and Mexico in Latin America. The rising demand for biopharmaceuticals and growing pressure to curtail the high development cost are compelling the biopharmaceutical industries to outsource research, development, and manufacturing to minimize cost and save time. Due to this, CDMOs in emerging nations are experiencing a high growth rate and are actively involved in the production and development of biopharmaceuticals. This is attributed to growing infrastructure and capacity development investments, low labor costs, improving adherence to global manufacturing standards, and increasing regulatory oversight.

The development of biosimilar therapeutics is gaining pace in developing economies like China and India. China is experiencing a spike in biopharmaceutical development. The Chinese government has undertaken several initiatives to develop and commercialize biosimilars. Some of these initiatives include developing multinational clinical centers and accelerating the approval process for special medicines. The introduction of the Marketing Authorization Holder (MAH) plan to launch biosimilars in China has allowed license holders to sell biosimilars through contract manufacturing.

These initiatives in emerging economies for bioproduction or research provide an opportunity for a higher demand for protein expression systems.

Key Findings in the Protein Expression Market Study:

In 2024, the Mammalian Cell Expression System Segment is Expected to Dominate the Market

Among the system type, the mammalian cell expression system segment is expected to account for the largest share of this market. This segment’s large market share is attributed to advantages like the low risk of cross-contamination, no need for post-translational modification, and wider acceptance for therapeutic applications.

In 2024, the Reagents Segment is Expected to Dominate the Market

Based on products & services, the protein expression market is segmented into instruments, kits & reagents, competent cells, expression vectors, and services. In 2024, the reagents segment is expected to account for the largest share of the protein expression market. The large market share of this segment is attributed to factors such as frequent use of them for research, therapeutics, or industrial purposes.

In 2024, the Research Segment is Expected to Exhibit Highest CAGR

Among the application, the research segment is expected to grow at the highest CAGR in the protein expression market. Factors such as a growing R&D expenditure, the emergence of new diseases, and a focus on pharma-academic collaboration for boosting research supported the growth of the market.

In 2024, the Contract Research Organizations Segment is Expected to Exhibit Highest CAGR

Based on end user, the protein expression market is segmented into pharmaceutical & biotechnology industry, contract research organizations, and academic & research institutes. In 2024, the contract research organizations segment is expected to exhibit the highest CAGR owing to the growing focus of many vendors on outsourcing and government initiatives for expanding research activities.

Asia-Pacific: Fastest-growing Regional Market

The growth of this market is driven by the increasing investments in life science research in developing countries such as China and India, and the growing preference for recombinant technology owing to advantages such as low risk of immune reaction, no interference of protein contaminants, and short production lead times as there is no need of purification process in recombinant technology. Thus, compared to traditional technology, recombinant is driving the growth of the protein expression market in Asia-Pacific.

Key Players:

The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market players in the past few years. The key players profiled in the protein expression market report are Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Takara Holdings Inc. (Japan), GenScript Biotech Corporation (U.S.), Qiagen N.V. (Germany), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), and BECTON, DICKINSON AND COMPANY (U.S.).

Scope of the Report:

Protein Expression Market Assessment, by System

• Mammalian Cell Expression System
  • Chinese Hamster Ovary (CHO) Cell Lines
  • HEK 293 Cell Lines
  • Other Mammalian Cell Lines
• Non-mammalian Cell Expression System
  • Bacterial Cell Lines
  • Insect Cell Lines
  • Yeast Cell Lines
  • Plant Cell Lines
  • Algal-based Cell Lines
• Cell-Free Expression System
  (Note: Other mammalian cell expression system includes Baby Hamster Kidney Cells, Non-secreting Murine Myeloma cells, and PER.C6.)

Protein Expression Market Assessment, by Product & Service

• Instruments
• Kits & Reagents
• Competent Cells
  • Chemically Competent Cells
  • Electrocompetent Cells
• Expression Vectors
• Services

Protein Expression Market Assessment, by Application

• Therapeutic
• Research
• Industrial

Protein Expression Market Assessment, by End User

• Pharmaceutical & Biotechnology Industry
• Academic & Research Institutes
• Contract Research Organizations (CROs)

Protein Expression Market Assessment, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Spain
  • Rest of Europe (RoE)
• Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
• Latin America
• Middle East & Africa

Key questions answered in the report: